SCHEMBL4252921

SCHEMBL4252921

O=C(Nc1cccc(Cl)c1)c1cnc(N2CCOCC2)c(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.67
▸ MAOB P27338 1/20 0.66
▸ P2RY12 Q9H244 1/20 0.56
▸ MEN1 O00255 4/20 0.55
▸ KMT2A Q03164 4/20 0.55
▸ SMN1; SMN2 Q16637 6/20 0.53
▸ NPC1 O15118 4/20 0.53
▸ RAB9A P51151 3/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ CASP3 P42574 1/20 0.53
▸ SENP7 Q9BQF6 1/20 0.53
▸ MAPT P10636 5/20 0.52
▸ HTT P42858 4/20 0.52
▸ LMNA P02545 4/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ P4HTM Q9NXG6 1/20 0.51
▸ DGAT1 O75907 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ MALT1 Q9UDY8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3687374 0.90 SLC2A1 (0.68) SLC2A1MAOBP2RY12MEN1KMT2A
SCHEMBL3677907 0.90 SLC2A1 (0.68) SLC2A1MAOBP2RY12MEN1KMT2A
SCHEMBL31107157 0.89 SLC2A1 (0.67) SLC2A1MAOBP2RY12MEN1KMT2A
SCHEMBL13930624 0.89 SLC2A1 (0.67) SLC2A1MAOBP2RY12MEN1KMT2A
SCHEMBL4258257 0.87 SLC2A1 (0.67) SLC2A1MAOBP2RY12MEN1KMT2A
SCHEMBL3683318 0.87 SLC2A1 (0.65) SLC2A1MAOBP2RY12SMN1; SMN2NPC1
SCHEMBL13930613 0.85 SLC2A1 (0.62) SLC2A1MAOBP2RY12SMN1; SMN2MAPT
SCHEMBL31107155 0.85 SLC2A1 (0.62) SLC2A1MAOBP2RY12SMN1; SMN2MAPT
SCHEMBL4247530 0.83 MAPT (0.69) SMN1; SMN2NPC1RAB9AKDM4ECASP3
3-Chloroaniline SCHEMBL3676148 0.82 SLC2A1 (0.61) SLC2A1MAOBP2RY12MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 — — US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 — — US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS GABBR1, GABBR2, CHRM2 SLC2A1 2534/4885MAOB 48/4885P2RY12 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback